XORTX Therapeutics IncTSXV:XRTXView on NASDAQ
- LAST PRICE3.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 3.4000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XRTX |
|---|---|---|
| 09:34 ET | 300 | 3.55 |
| 09:39 ET | 200 | 3.44 |
| 11:24 ET | 2300 | 3.4 |
Apr 30, 2024
XORTX Reprices Warrants Issued in Connection with Previous Private Placements, from 1:54PM ET on Tuesday Apr 30, 2024 by Dow Jones
1:54PM ET on Tuesday Apr 30, 2024 by Dow Jones
Apr 22, 2024
XORTX Announces Publication of Key Research in ADPKD, from 7:00AM ET on Monday Apr 22, 2024 by Dow Jones
7:00AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 8, 2024
XORTX Welcomes New Member to the Board of Directors, from 7:30AM ET on Monday Apr 08, 2024 by Dow Jones
7:30AM ET on Monday Apr 08, 2024 by Dow JonesXORTX Announces Participation in Spring 2024 Investor Conferences, from 7:00AM ET on Monday Apr 08, 2024 by Dow Jones
7:00AM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XORTX Therapeutics Inc | 7.0M | -2.2x | --- |
Revive Therapeutics Ltd | 10.5M | -1.9x | --- |
Telo Genomics Corp | 10.7M | -3.2x | --- |
Marvel Biosciences Corp | 6.2M | -2.5x | --- |
BetterLife Pharma Inc | 13.1M | -5.5x | --- |
Rakovina Therapeutics Inc | 6.0M | -2.3x | --- |
Company Information
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Contact Information
- Headquarters
- 3710 - 33rd Street NWCALGARY, AB, Canada T2L 2M1
- Phone
- 403-455-7727
- Fax
- 403-607-2621
Executives
- Independent Non-Executive Chairman of the Board
- Anthony Giovinazzo
- President, Chief Executive Officer, Director
- Allen Davidoff
- Interim Chief Financial Officer
- James Fairbairn
- Chief Business Officer
- Stacy Evans
- Chief Medical Officer
- Stephen Haworth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.0M |
XORTX Therapeutics Inc does not pay a dividend. | |
Beta | -0.13 |
EPS | $-1.52 |
Book Value | $3.17 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
